The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead
pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Astellas, about why partnering with patients is the corners
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
